DEF 14A: Phreesia, Inc. Announces Details for 2024 Annual Stockholders Meeting

Phreesia, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Summary

• Phreesia, Inc. is holding its 2024 Annual Meeting of Stockholders on June 26, 2024, virtually.
• Stockholders will vote on three proposals: electing three Class II directors, ratifying the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending January 31, 2025, and approving, on a non-binding, advisory basis, the compensation of the named executive officers (NEOs).
• The Board recommends voting FOR all director nominees, FOR the ratification of KPMG, and FOR the approval of NEO compensation.
• The record date for determining stockholders eligible to vote is May 1, 2024.
• As of the record date, there were 57,319,811 shares of common stock outstanding.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/PHR2024.
• The company's revenue was $356.3 million in fiscal year 2024, up 27% year-over-year.
• The average number of healthcare services clients (AHSCs) were 3,601 in fiscal year 2024, up 26% year-over-year.
• The net loss was $136.9 million in fiscal year 2024, as compared to $176.1 million in fiscal year 2023.
• The adjusted EBITDA was negative $35.4 million in fiscal 2024, as compared to negative $92.5 million in fiscal 2023.
• Cash and cash equivalents as of January 31, 2024 was $87.5 million, down from $176.7 million as of January 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative financial results, with revenue growth offset by continued losses and a decrease in cash reserves. The overall tone is neutral, focusing on factual information.

Positives

• Revenue increased by 27% year-over-year, reaching $356.3 million in fiscal year 2024.
• The number of healthcare services clients increased by 26% year-over-year, totaling 3,601 in fiscal year 2024.
• Net loss decreased from $176.1 million in fiscal year 2023 to $136.9 million in fiscal year 2024.
• Adjusted EBITDA improved from negative $92.5 million in fiscal year 2023 to negative $35.4 million in fiscal year 2024.

Negatives

• Healthcare services revenue per AHSC decreased by 1% year-over-year in fiscal year 2024.
• Net loss was $136.9 million in fiscal year 2024.
• Adjusted EBITDA was negative $35.4 million in fiscal year 2024.
• Cash and cash equivalents decreased from $176.7 million as of January 31, 2023 to $87.5 million as of January 31, 2024.

Risks

• The company is still operating at a net loss, indicating ongoing financial challenges.
• Adjusted EBITDA remains negative, although it has improved year-over-year.
• Cash reserves have significantly decreased, which could impact future operations and investments.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the proposals for the annual meeting.

Management Comments

• Chaim Indig, Chief Executive Officer, expressed gratitude for stockholders' ongoing support and interest in Phreesia.

Industry Context

The document provides information relevant to the healthcare technology industry, particularly regarding software solutions for healthcare organizations and communication channels for life sciences companies.

Comparison to Industry Standards

• The compensation committee reviews the compensation levels and practices of a group of comparable healthcare IT and SaaS companies.
• The companies in this compensation peer group were selected based on their similarity to us in characteristics such as market capitalization, size, shareholder return and industry focus.
• The primary criteria for our peers were that they are in software industry and their market capitalization was similar to ours.
• The compensation committee viewed the peer group as generally reflecting both our labor market and size at the time the peer group was approved.
• The compensation committee set target annual long-term incentive awards so that they were below the median of our peer group for fiscal 2024 using the notional $20 share price that was similar to the stock price when equity grant discussions began in the third fiscal quarter.

Management Changes

Related Party Transactions

• During the fiscal year ended January 31, 2024, Phreesia entered into statements of work with an advertising company for advertisements placed by Jazz Pharmaceuticals plc, or Jazz, pursuant to which Phreesia recognized revenue of approximately $1.2 million.
• On November 30, 2021, Phreesia entered into a Master SaaS Services Agreement with Sumo Logic, Inc, or Sumo Logic, which replaced our agreement with Sumo Logic that we entered into in February of 2021.
• The spouse of David Linetsky, our SVP, Life Sciences, is a non-executive officer employee of Phreesia.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's direction and governance.
• Employees are affected by the company's compensation policies and benefit plans.
• Customers (healthcare organizations and life sciences companies) are indirectly impacted by the company's financial performance and strategic decisions.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, KPMG, governance, financial results, Phreesia